Which WHO low‑osmolarity oral rehydration solution (ORS) should be used for rehydration when the specialized ReSoMal formulation is unavailable, and what is the recommended dosing schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Use Standard WHO Low-Osmolarity ORS When ReSoMal is Unavailable

When ReSoMal is not available, use standard WHO low-osmolarity ORS (osmolarity <250 mmol/L) for rehydration in all patients, including those with severe acute malnutrition. Recent high-quality evidence demonstrates that standard WHO-ORS is safe and equally effective as ReSoMal, without increased risk of sodium overload or fluid complications 1.

Key Evidence Supporting Standard WHO-ORS

The 2026 GASTROSAM trial—the most recent and highest quality study—directly compared WHO-ORS to ReSoMal in 415 severely malnourished children with dehydration 2. This landmark study found:

  • No difference in sodium changes between groups (5.0 mmol/L with WHO-ORS vs 5.3 mmol/L with ReSoMal)
  • No fluid overload events (pulmonary edema or cardiac overload) in either group
  • Similar mortality rates at 28 days (9% vs 12%, p=0.39)
  • Conclusion: WHO-ORS is safe regardless of nutritional status

This directly contradicts older theoretical concerns about sodium overload in malnourished children that led to ReSoMal's development.

Recommended Dosing Schedule

For Mild to Moderate Dehydration 1:

Rehydration Phase:

  • Infants and children: 50-100 mL/kg over 3-4 hours
  • Adolescents and adults (≥30 kg): 2-4 L over 3-4 hours

Maintenance/Replacement Phase:

  • Children <10 kg: 60-120 mL per diarrheal stool or vomiting episode (up to ~500 mL/day)
  • Children >10 kg: 120-240 mL per episode (up to ~1 L/day)
  • Adolescents/adults: Ad libitum, up to ~2 L/day

For Severe Dehydration 1:

  • Initial management: IV isotonic crystalloids (lactated Ringer's or normal saline) until pulse, perfusion, and mental status normalize
  • Transition to ORS: Once stabilized, complete remaining deficit replacement with standard WHO-ORS using the dosing above

Important Clinical Considerations

Commercially Available WHO-ORS Formulations 1:

  • Pedialyte Liters (Abbott Nutrition)
  • CeraLyte (Cero Products)
  • Enfalac Lytren (Mead Johnson)

What NOT to Use 1:

Avoid apple juice, Gatorade, and commercial soft drinks—these lack appropriate electrolyte composition and osmolarity.

Special Populations

Malnourished infants with severe dehydration 1:

  • Consider smaller-volume, frequent boluses of 10 mL/kg IV due to reduced cardiac capacity
  • Transition to standard WHO-ORS once stabilized

Contraindications to oral rehydration 1:

  • Severe dehydration with shock or altered mental status (use IV first)
  • Ileus
  • Intractable vomiting despite nasogastric administration
  • Risk factors for aspiration

Nasogastric Administration 1:

If oral intake is not tolerated, administer WHO-ORS via nasogastric tube in patients with:

  • Normal mental status
  • Moderate dehydration who cannot drink
  • Weakness or refusal to drink adequately

Why This Matters

The IDSA guidelines 1 provide strong recommendations (strong, moderate evidence) that low-osmolarity ORS is first-line therapy for mild to moderate dehydration from any cause of diarrhea, in all age groups. The 2002 WHO shift from standard ORS (311 mmol/L) to low-osmolarity ORS (<250 mmol/L) was based on reduced need for IV therapy and decreased stool output 1.

Critical pitfall: The theoretical concerns about sodium overload in malnutrition that drove ReSoMal development have not been validated in clinical practice. In fact, ReSoMal may increase hyponatremia risk 3, 4. The GASTROSAM trial 2 definitively shows standard WHO-ORS is safe in malnourished children, simplifying treatment protocols.

Safety Profile

Low-osmolarity WHO-ORS is safe in both hypernatremia and hyponatremia (except when edema is present) 1. Multiple studies confirm no increased risk of hyponatremia compared to higher osmolarity solutions 5, 6, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.